Back to Explorer

Unique Device Identification: Direct Marking of Devices : Guidance for Industry and Food and Drug Administration Staff

FinalCenter for Devices and Radiological Health Center for Biologics Evaluation and Research11/17/2017

Description

This documentwill assist industry, particularly labelers, as defined under 21 CFR 801.3, and FDA staff in understanding FDA’s requirements for direct marking of devices for unique device identification purposes. Under 21 CFR 801.45, "[a] device that must bear a unique device identifier (UDI) on its label must also bear a permanent marking providing the UDI on the device itself if the device is intended to be used more than once and intended to be reprocessed before each use." This guidance defines some terms used in the Agency’s regulations pertaining to the UDI direct marking requirements, including how FDA interprets the term "intended to be reprocessed" as used in 21 CFR 801.45. For additional background on the UDI system, see the Unique Device Identification System Final Rule, published on September 24, 2013 (78 FR 58786) (the UDI Rule -https://www.gpo.gov/fdsys/pkg/FR-2013-09-24/pdf/2013-23059.pdf).

Scope & Applicability

Product Classes

4
Class III Device

Generally recommended for Enhanced Documentation; Regulatory classification mentioned for implantable sensors and HPV tests; Mentioned in the context of an in vitro nucleic acid test for CMV DNA.

Class II Device

Devices subject to section 522 postmarket surveillance orders; devices subject to postmarket surveillance orders

Class I Device

Low risk medical devices

Life-sustaining and life-supporting devices

Devices requiring direct marking by 9/24/2015.

Stakeholders

2
labeler

Person who causes a label to be applied to a device for commercial distribution; Entity required to enter DI and attribute information into GUDID; Entity responsible for GUDID account and device information; Responsible for ensuring DI record information is accurate and up-to-date.; Entity identified by a GUDID account; Entity responsible for GUDID data and recordkeeping.

FDA UDI Help Desk

requests for instructions may be submitted using the online form

Regulatory Context

Attributes

3
Technological feasibility

Factor in determining if direct marking is required

effectiveness

alternative would better ensure the effectiveness of the device

safety

evaluating pubertal development for evaluation of safety

Identified Hazards

Hazards

1
Microbial life

Target of high-level disinfection

Related CFR Sections (14)

Related Warning Letters (10)

  • CGMP/QSR/Medical Devices/Adulterated

    DFI Co., Ltd.

    2025-06-03
  • CGMP/QSR/Medical Devices/Adulterated

    NeuroSync, Inc.

    2025-05-20
  • CGMP/QSR/Medical Devices/PMA/Adulterated/Misbranded

    ICU Medical

    2025-04-22
  • CGMP/QSR/Medical Devices/Adulterated

    EpiCare Acquisitions, LLC

    2025-04-08
  • CGMP/QSR/Medical Devices/Adulterated

    Owens & Minor, Inc. dba American Contract Systems, Inc.

    2024-11-12
  • CGMP/QSR/Medical Devices/Adulterated

    Rolence Ent. Inc.

    2024-11-08
  • CGMP/QSR/Medical Devices/Adulterated/Misbranded

    Argon Medical Productions & Vertrieb Gesellschaft MBH & CO

    2024-10-29
  • CGMP/QSR/Medical Devices/Adulterated

    Wissner-Bosserhoff GmbH

    2024-09-03
  • CGMP/QSR/Medical Devices/Adulterated

    Jiangsu Shenli Medical Production Co., Ltd.

    2024-07-18
  • CGMP/QSR/Medical Devices/Adulterated/Misbranded

    Techlem Medical Corporation

    2024-06-04

See Also (8)